Intensity Therapeutics Inc
Company Profile
Business description
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Contact
1 Enterprise Drive
Suite 430
SheltonCT06484-4779
USAT: +1 203 221-7381
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
ASX giant falls short on copper guidance
stocks
Pure-play data center share raises capital to fund AI demand
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,974.70 | 32.40 | -0.36% |
| CAC 40 | 8,340.11 | 1.30 | 0.02% |
| DAX 40 | 24,846.69 | 15.71 | 0.06% |
| Dow JONES (US) | 51,782.31 | 364.11 | -0.70% |
| FTSE 100 | 10,524.76 | 75.61 | -0.71% |
| HKSE | 25,143.05 | 580.81 | 2.36% |
| NASDAQ | 25,524.82 | 4.58 | 0.02% |
| Nikkei 225 | 64,141.12 | 2,694.42 | -4.03% |
| NZX 50 Index | 13,696.03 | 1.35 | 0.01% |
| S&P 500 | 7,440.98 | 16.71 | -0.22% |
| S&P/ASX 200 | 8,791.30 | 31.00 | -0.35% |
| SSE Composite Index | 3,796.28 | 32.13 | 0.85% |